Monitoring of human papillomavirus vaccination
J Dillner, M Arbyn, E Unger… - Clinical & Experimental …, 2011 - academic.oup.com
Persistent infection with oncogenic human papillomavirus (HPV) is a necessary causal
factor in the development of cervical cancer. Moreover, HPV, predominately type 16 and to a …
factor in the development of cervical cancer. Moreover, HPV, predominately type 16 and to a …
Translational mini-review series on vaccines: monitoring of human papillomavirus vaccination
J Dillner, M Arbyn, L Dillner - Clinical & Experimental …, 2007 - academic.oup.com
Persistent infection with oncogenic human papillomavirus (HPV) is a necessary cause of
cervical cancer. Moreover, HPV type 16 (and to a lesser degree HPV type 18) is linked with …
cervical cancer. Moreover, HPV type 16 (and to a lesser degree HPV type 18) is linked with …
Indications and efficacy of the human papillomavirus vaccine
AA Hakim, PS Lin, S Wilczynski, K Nguyen… - … treatment options in …, 2007 - Springer
Opinion statement In the United States, there are 11,150 cases and 3670 deaths projected
due to invasive cervical cancer for 2007. Approximately 500,000 new cases and 274,000 …
due to invasive cervical cancer for 2007. Approximately 500,000 new cases and 274,000 …
Prophylactic HPV vaccines: new interventions for cancer control
E Barr, HL Sings - Vaccine, 2008 - Elsevier
Human Papillomavirus (HPV) infection causes cervical cancer, a significant portion of anal,
vulvar, vaginal, and oropharyngeal cancers, genital warts, and recurrent respiratory …
vulvar, vaginal, and oropharyngeal cancers, genital warts, and recurrent respiratory …
Human papillomavirus vaccines
J Schiller, D Lowy, L Markowithz - Vaccines. 6th ed. Philadelphia …, 2012 - books.google.com
Human papilloma virus (HPV) infections, which are common, produce epithelial lesions of
the nongenital and genital skin and mucous membranes. Although most infections are …
the nongenital and genital skin and mucous membranes. Although most infections are …
Human papillomavirus vaccination
JT Cox, JM Palefsky - UpToDate. Waltham, MA. Accessed September, 2018 - uptodate.com
INTRODUCTION—Human papillomavirus (HPV) is a sexually transmitted pathogen that
causes anogenital and oropharyngeal disease in males and females. Persistent viral …
causes anogenital and oropharyngeal disease in males and females. Persistent viral …
[HTML][HTML] Human papillomavirus vaccine efficacy and effectiveness against cancer
S Kamolratanakul, P Pitisuttithum - Vaccines, 2021 - mdpi.com
Human papillomavirus (HPV) is the most common sexually transmitted infection, with 15
HPV types related to cervical, anal, oropharyngeal, penile, vulvar, and vaginal cancers …
HPV types related to cervical, anal, oropharyngeal, penile, vulvar, and vaginal cancers …
Prophylactic human papillomavirus vaccines: the beginning of the end of cervical cancer
WAA Tjalma, M Arbyn, J Paavonen… - International Journal of …, 2004 - ijgc.bmj.com
Persistent infection with one of the oncogenic human papillomavirus (HPV) types is a
necessity for the development of cervical cancer. By HPV vaccination, cervical cancer could …
necessity for the development of cervical cancer. By HPV vaccination, cervical cancer could …
Sound efficacy of prophylactic HPV vaccination: basics and implications
M Lehtinen, J Paavonen - Oncoimmunology, 2012 - Taylor & Francis
Prophylactic human papillomavirus vaccine efficacy is almost too good to be true. The
benefits of herd immunity will, however, not be gained without high vaccine coverage. Here …
benefits of herd immunity will, however, not be gained without high vaccine coverage. Here …
[HTML][HTML] Vaccines against human papillomavirus infections: protection against cancer, genital warts or both?
EA Joura, S Pils - Clinical Microbiology and Infection, 2016 - Elsevier
Since 2006, three vaccines against infections and disease caused by human papillomavirus
(HPV) became available in Europe—in 2006 a quadrivalent HPV 6/11/16/18 vaccine, in …
(HPV) became available in Europe—in 2006 a quadrivalent HPV 6/11/16/18 vaccine, in …